PLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pliant Therapeutics Inc (PLRX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While hedge funds are increasing their positions, the financial performance is weak, with significant YoY declines in net income and EPS. Additionally, there are no strong technical or proprietary trading signals to suggest an immediate entry point. The options data indicates low put-call ratios, but this alone is insufficient to justify a buy. Given the lack of positive news, no recent congress trading data, and no clear analyst rating trends, it is better to hold off on investing in this stock for now.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 67.272, and moving averages are converging, suggesting no clear trend. The stock is trading near its R1 resistance level of 1.306, with a pre-market price of 1.31. Overall, the technical indicators do not strongly support a buy decision.
Hedge funds are increasing their positions, with a 138.46% increase in buying activity over the last quarter.
No significant insider trading trends, no recent news, weak financial performance with declining net income and EPS, and no recent congress trading data.
In Q3 2025, revenue remained at 0 with no YoY growth. Net income dropped significantly by -54.47% YoY to -$26.3M, and EPS fell by -54.74% YoY to -0.43. Gross margin remained unchanged at 0.
No data available for analyst ratings or price target changes.
